Literature DB >> 24190619

Unique neuromyelitis optica pathology produced in naïve rats by intracerebral administration of NMO-IgG.

Nithi Asavapanumas1, Julien Ratelade, A S Verkman.   

Abstract

Animal models of neuromyelitis optica (NMO) are needed for elucidation of disease mechanisms and for testing new therapeutics. Prior animal models of NMO involved administration of human anti-aquaporin-4 immunoglobulin G antibody (NMO-IgG) to rats with pre-existing neuroinflammation, or to naïve mice supplemented with human complement. We report here the development of NMO pathology following passive transfer of NMO-IgG to naïve rats. A single intracerebral infusion of NMO-IgG to adult Lewis rats produced robust lesions around the needle track in 100 % of rats; at 5 days there was marked loss of aquaporin-4 (AQP4), glial fibrillary acidic protein (GFAP) and myelin, granulocyte and macrophage infiltration, vasculocentric complement deposition, blood-brain barrier disruption, microglial activation and neuron death. Remarkably, a distinct 'penumbra' was seen around lesions, with loss of AQP4 but not of GFAP or myelin. No lesions or penumbra were seen in rats receiving control IgG. The size of the main lesion with loss of myelin was greatly reduced in rats made complement-deficient by cobra venom factor or administered NMO-IgG lacking complement-dependent cytotoxicity (CDC) effector function. However, the penumbra was seen under these conditions, suggesting a complement-independent pathogenesis mechanism. The penumbra was absent with NMO-IgG lacking both CDC and antibody-dependent cellular cytotoxicity (ADCC) effector functions. Finally, lesion size was significantly reduced after macrophage depletion with clodronate liposomes. These results: (i) establish a robust, passive-transfer model of NMO in rats that does not require pre-existing neuroinflammation or complement administration; (ii) implicate ADCC as responsible for a unique type of pathology also seen in human NMO; and (iii) support a pathogenic role of macrophages in NMO.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24190619      PMCID: PMC3954950          DOI: 10.1007/s00401-013-1204-8

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  48 in total

Review 1.  Cobra venom factor: Structure, function, and humanization for therapeutic complement depletion.

Authors:  Carl-Wilhelm Vogel; David C Fritzinger
Journal:  Toxicon       Date:  2010-04-22       Impact factor: 3.033

2.  Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord.

Authors:  Kristina A Kigerl; John C Gensel; Daniel P Ankeny; Jessica K Alexander; Dustin J Donnelly; Phillip G Popovich
Journal:  J Neurosci       Date:  2009-10-28       Impact factor: 6.167

3.  Anti-aquaporin-4 antibody induces astrocytic cytotoxicity in the absence of CNS antigen-specific T cells.

Authors:  Makoto Kinoshita; Yuji Nakatsuji; Takashi Kimura; Masayuki Moriya; Kazushiro Takata; Tatsusada Okuno; Atsushi Kumanogoh; Koji Kajiyama; Hiroo Yoshikawa; Saburo Sakoda
Journal:  Biochem Biophys Res Commun       Date:  2010-02-25       Impact factor: 3.575

4.  Binding affinity and specificity of neuromyelitis optica autoantibodies to aquaporin-4 M1/M23 isoforms and orthogonal arrays.

Authors:  Jonathan M Crane; Chiwah Lam; Andrea Rossi; Tripta Gupta; Jeffrey L Bennett; A S Verkman
Journal:  J Biol Chem       Date:  2011-03-21       Impact factor: 5.157

Review 5.  AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance.

Authors:  Sven Jarius; Brigitte Wildemann
Journal:  Nat Rev Neurol       Date:  2010-07       Impact factor: 42.937

6.  Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica.

Authors:  Jeffrey L Bennett; Chiwah Lam; Sudhakar Reddy Kalluri; Philippe Saikali; Katherine Bautista; Cecily Dupree; Magdalena Glogowska; David Case; Jack P Antel; Gregory P Owens; Don Gilden; Stefan Nessler; Christine Stadelmann; Bernhard Hemmer
Journal:  Ann Neurol       Date:  2009-11       Impact factor: 10.422

7.  Reactive astrocytes form scar-like perivascular barriers to leukocytes during adaptive immune inflammation of the CNS.

Authors:  Rhonda R Voskuhl; R Scott Peterson; Bingbing Song; Yan Ao; Laurie Beth J Morales; Seema Tiwari-Woodruff; Michael V Sofroniew
Journal:  J Neurosci       Date:  2009-09-16       Impact factor: 6.167

8.  Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice.

Authors:  Samira Saadoun; Patrick Waters; B Anthony Bell; Angela Vincent; A S Verkman; Marios C Papadopoulos
Journal:  Brain       Date:  2010-01-04       Impact factor: 13.501

9.  Neuromyelitis optica: Passive transfer to rats by human immunoglobulin.

Authors:  Makoto Kinoshita; Yuji Nakatsuji; Takashi Kimura; Masayuki Moriya; Kazushiro Takata; Tatsusada Okuno; Atsushi Kumanogoh; Koji Kajiyama; Hiroo Yoshikawa; Saburo Sakoda
Journal:  Biochem Biophys Res Commun       Date:  2009-06-21       Impact factor: 3.575

10.  Macrophages regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor-C-dependent buffering mechanism.

Authors:  Agnes Machnik; Wolfgang Neuhofer; Jonathan Jantsch; Anke Dahlmann; Tuomas Tammela; Katharina Machura; Joon-Keun Park; Franz-Xaver Beck; Dominik N Müller; Wolfgang Derer; Jennifer Goss; Agata Ziomber; Peter Dietsch; Hubertus Wagner; Nico van Rooijen; Armin Kurtz; Karl F Hilgers; Kari Alitalo; Kai-Uwe Eckardt; Friedrich C Luft; Dontscho Kerjaschki; Jens Titze
Journal:  Nat Med       Date:  2009-05-03       Impact factor: 53.440

View more
  31 in total

1.  Noninvasive, Targeted Creation of Neuromyelitis Optica Pathology in AQP4-IgG Seropositive Rats by Pulsed Focused Ultrasound.

Authors:  Xiaoming Yao; Matthew S Adams; Peter D Jones; Chris J Diederich; Alan S Verkman
Journal:  J Neuropathol Exp Neurol       Date:  2019-01-01       Impact factor: 3.685

2.  Rescue effects of intravenous immunoglobulin on optic nerve degeneration in a rat model of neuromyelitis optica.

Authors:  Sho Nobuyoshi; Akiyasu Kanamori; Yoshiko Matsumoto; Makoto Nakamura
Journal:  Jpn J Ophthalmol       Date:  2016-06-07       Impact factor: 2.447

Review 3.  Neuromyelitis optica spectrum disorders.

Authors:  Eoin P Flanagan; Brian G Weinshenker
Journal:  Curr Neurol Neurosci Rep       Date:  2014-09       Impact factor: 5.081

4.  Human immunoglobulin G reduces the pathogenicity of aquaporin-4 autoantibodies in neuromyelitis optica.

Authors:  Julien Ratelade; Alex J Smith; A S Verkman
Journal:  Exp Neurol       Date:  2014-03-14       Impact factor: 5.330

Review 5.  Treatment of neuromyelitis optica: state-of-the-art and emerging therapies.

Authors:  Marios C Papadopoulos; Jeffrey L Bennett; Alan S Verkman
Journal:  Nat Rev Neurol       Date:  2014-08-12       Impact factor: 42.937

6.  Inhibitor(s) of the classical complement pathway in mouse serum limit the utility of mice as experimental models of neuromyelitis optica.

Authors:  Julien Ratelade; A S Verkman
Journal:  Mol Immunol       Date:  2014-06-28       Impact factor: 4.407

Review 7.  Experimental models of neuromyelitis optica: current status, challenges and future directions.

Authors:  Minshu Li; Yaping Yan
Journal:  Neurosci Bull       Date:  2015-06-24       Impact factor: 5.203

8.  Myelin Oligodendrocyte Glycoprotein-IgG Contributes to Oligodendrocytopathy in the Presence of Complement, Distinct from Astrocytopathy Induced by AQP4-IgG.

Authors:  Ling Fang; Xinmei Kang; Zhen Wang; Shisi Wang; Jingqi Wang; Yifan Zhou; Chen Chen; Xiaobo Sun; Yaping Yan; Allan G Kermode; Lisheng Peng; Wei Qiu
Journal:  Neurosci Bull       Date:  2019-04-30       Impact factor: 5.203

9.  The intrinsic pathogenic role of autoantibodies to aquaporin 4 mediating spinal cord disease in a rat passive-transfer model.

Authors:  Christian Geis; Christian Ritter; Christoph Ruschil; Andreas Weishaupt; Benedikt Grünewald; Guido Stoll; Trygve Holmoy; Tatsuro Misu; Kazuo Fujihara; Bernhard Hemmer; Christine Stadelmann; Jeffrey L Bennett; Claudia Sommer; Klaus V Toyka
Journal:  Exp Neurol       Date:  2014-12-24       Impact factor: 5.330

10.  Bystander mechanism for complement-initiated early oligodendrocyte injury in neuromyelitis optica.

Authors:  Lukmanee Tradtrantip; Xiaoming Yao; Tao Su; Alex J Smith; Alan S Verkman
Journal:  Acta Neuropathol       Date:  2017-05-31       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.